Description: Mural Oncology plc, a clinical-stage oncology company, focuses on discovering and developing immunotherapies for the treatment of patients with cancer. The company's lead product candidate includes nemvaleukin alfa for the treatment of mucosal melanoma as a monotherapy and platinum-resistant ovarian cancer in combination with pembrolizumab. It also develops nemvaleukin to treat cutaneous melanoma and advanced solid tumors. The company is also developing engineered interleukin-18 and tumor-targeted interleukin-12 programs. Mural Oncology plc was incorporated in 2017 and is based in Dublin, Ireland.
Home Page: www.muraloncology.com
10 Earlsfort Terrace
Dublin,
D02 T380
Ireland
Phone:
353 1 905 8020
Officers
| Name | Title |
|---|---|
| Ms. Caroline J. Loew Ph.D. | President, CEO & Director |
| Mr. Adam D. Cutler B.A. | CFO, Principal Financial Officer & Principal Accounting Officer |
| Dr. Vicki L. Goodman M.D. | Chief Medical Officer |
| Ms. Maiken Keson-Brookes | Chief Legal Officer |
| Mr. Justin Levine | Head of Human Resources & VP of Human Resources |
Exchange: NASDAQ
Country: US : United States of America
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 0.3664 |
| Price-to-Sales TTM: | 0 |
| IPO Date: | 2023-11-16 |
| Fiscal Year End: | December |
| Full Time Employees: | 107 |